EyeGene Inc - ESG Rating & Company Profile powered by AI
Full Sustainability assessment of EyeGene Inc are accessed by logging in. This Disclosure rating includes seventeen United Nations SDGs including: 'Clean Water & Sanitation', 'Sustainable Cities & Communities' and 'Peace, Justice & Strong Institutions'. This analysis of EyeGene Inc employs data points from across the internet and also from available disclosures by EyeGene Inc.
EyeGene Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1967 | Hospira Inc | 0.3 | Low |
| 1967 | PRA Health Sciences Inc | 0.3 | Low |
| 1970 | EyeGene Inc | 0.0 | Low |
| 1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
| 1970 | CTC Bio Inc | 0.0 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does EyeGene Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes EyeGene Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes EyeGene Inc report the average age of the workforce?
Sign up for free to unlockDoes EyeGene Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes EyeGene Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes EyeGene Inc disclose cybersecurity risks?
Sign up for free to unlockDoes EyeGene Inc offer flexible work?
Sign up for free to unlockDoes EyeGene Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes EyeGene Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes EyeGene Inc conduct supply chain audits?
Sign up for free to unlockDoes EyeGene Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes EyeGene Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes EyeGene Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes EyeGene Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes EyeGene Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes EyeGene Inc disclose water use targets?
Sign up for free to unlockDoes EyeGene Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid EyeGene Inc have a product recall in the last two years?
Sign up for free to unlockDoes EyeGene Inc disclose incidents of discrimination?
Sign up for free to unlockDoes EyeGene Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas EyeGene Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes EyeGene Inc disclose parental leave metrics?
Sign up for free to unlockDoes EyeGene Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes EyeGene Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes EyeGene Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes EyeGene Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes EyeGene Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes EyeGene Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs EyeGene Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes EyeGene Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes EyeGene Inc disclose its waste policy?
Sign up for free to unlockDoes EyeGene Inc report according to TCFD requirements?
Sign up for free to unlockDoes EyeGene Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes EyeGene Inc disclose energy use targets?
Sign up for free to unlockDoes EyeGene Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes EyeGene Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for EyeGene Inc
These potential risks are based on the size, segment and geographies of the company.
EyeGene Inc., a biotechnology company, engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company's products in pipeline include EG-Mirotin, a Phase IIa clinical trial product candidate for the treatment of diabetic retinopathy; EG-Decorin, a Phase I/II clinical trial product for the treatment for pressure ulcers; EG-Myocin, a product that is in Phase II clinical trials for the treatment of heart muscle; and EG-HPV, a product that completed Phase I clinical trial for the treatment of cervical cancer. Its products in pipeline also include EG-TB for the treatment of tuberculosis; and EG-HZ, which is in preclinical trials for the treatment of herpes zoster. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.